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adherence to diabetes medications than the comparison group (p=0.15). After the 
program, percent adherent grew 29.7% over baseline (p<0.01) net of trends in the 
comparison group. A smaller impact was observed for cardiovascular 
medications. Total spending (employer spending plus patient out-of-pocket 
spending) in the value-based program group was no different than the 
comparison group (p=0.11). Falsification tests of asthma and migraine 
medication utilization, showed no significant impact (p>.50). CONCLUSIONS: 
Results through the first twelve months of the program show that waiving 
copayments for all family members of a patient with diabetes can improve 
adherence to diabetes and cardiovascular services, which can lead to 
improvements in health outcomes.  
 
MA2  
BEYOND AVERAGE ADHERENCE: TEMPORAL PATTERNS OF MEDICATION 
ADHERENCE PREDICT HOSPITALIZATION RISK MORE ACCURATELY THAN THE 
MEDICATION POSSESSION RATIO  
Signorovitch J, Chopra P, Cheng D, Ayyagari R, Wu EQ 
Analysis Group, Inc., Boston, MA, USA  
OBJECTIVES: A patient’s temporal pattern of medication adherence may contain 
signals for clinical risks that are not captured by aggregate measures such as the 
medication possession ratio (MPR). We used hierarchical clustering to identify 
natural adherence patterns to dornase alfa in patients with cystic fibrosis (CF), 
and assessed whether these patterns were associated with hospitalization risk. 
METHODS: CF patients with a dornase alfa prescription followed by ≥1 year of 
health plan enrollment were identified in a national claims database (2005 - 
2011). Hierarchical clustering was used to identify common patterns of 
adherence over time based on prescription fills. To evaluate the clinical and 
economic meaningfulness of the clusters, their association with CF-related 
hospitalization risk was assessed using Poisson regression with adjustment for 
MPR and other characteristics. RESULTS: A total of 985 CF patients with ≥1 
prescription for dornase alfa were included. Average MPR was 45%. Half of the 
patients experienced hospitalization. Clustering identified six adherence 
patterns: 1) high; 2) low→high; 3) low →lower; 4) high→ow; 5) periodic; and 6) 
low. MPR distributions overlapped between clusters. In the Poisson regression, 
each 1% increase in MPR was significantly (p<0.05) associated with an 
approximate 1% reduction in hospitalization risk. Including effects of cluster 
membership into the model with MPR significantly improved fit (P<0.001). Even 
after adjusting for MPR, hospitalization risk varied significantly across clusters, 
and, relative to cluster 1, was increased by 97%, 115%, 52%, 286% and 57% in 
clusters 2 through 6, respectively. The predictive significance of the clusters was 
robust to further adjustment for quadratic effects of MPR. CONCLUSIONS: In this 
study of CF patients, temporal patterns of medication adherence predicted 
hospitalization risk more accurately than MPR alone. Temporal adherence 
patterns beyond MPR may have clinical and economic utility across therapeutic 
areas and warrant further study.  
 
MA3  
REVISION AND VALIDATION OF THE MEDICATION ADHERENCE REASONS 
SCALE (MAR –SCALE)  
Unni EJ1, Farris K2, Olson J3 
1Roseman University of Health Sciences College of Pharmacy, South Jordan, UT, USA, 2The 
University of Michigan, Ann Arbor, MI, USA, 3Intermountain Medical Center, Murray, UT, USA  
OBJECTIVES: Medication non-adherence is a complex phenomenon that requires 
tailored interventions to improve it. A new self-reported measure of medication 
non-adherence was developed based on the commonly reported reasons 
underlying non-adherence. The goal of the new scale was to match the items in 
the scale with tailored interventions. The objectives of this study were to revise 
the original Medication Adherence Reasons Scale (MAR-Scale) based on expert 
opinion and cognitive interviewing and establish the psychometric properties of 
the scale. METHODS: A cross sectional design was used in collaboration with the 
Intermountain Medical Center Outpatient clinic for cholesterol lowering (CLM) 
and asthma maintenance medications (AMM). The study was conducted in two 
phases: Phase 1 - the original MAR-Scale was revised based on expert opinion 
and cognitive interviewing, Phase 2 - the revised MAR-Scale was tested for 
psychometric properties in a random sample of 350 subjects each on CLM and 
AMM. RESULTS: Revisions were made based on expert opinion that included 
asking a global question about adherence in the past 7 days, simplifying the 
items and converting them into first person sentences, objective anchoring of 
the scale, and expanding the “forgetfulness” item. Cognitive interviewing added 
one additional item to the survey. The MAR- Scale identified 48% of the CLM 
respondents and 65% of the AMM respondents as non-adherents. An exploratory 
factor analysis identified four domains in each medication with Cronbach alpha 
ranging from 0.848 to 0.953 in CLM and 0.827 to 0.891 in AMM. For validity, the 
scale exhibited significant correlations (0.434 for CLM and 0.539 for AMM at 
p<0.01) with the well validated Morisky scale and also had significant negative 
correlation with self-efficacy (-0.226 for CLM and -0.329 for AMM at p < 0.01). 
CONCLUSIONS: The study resulted in a revised MAR-Scale that demonstrated 
better psychometric properties than the original scale.  
 
MA4  
USING LATENT CLASS PROBABILITY ESTIMATION AND RESIDUAL INCLUSION 
TO ADDRESS CONFOUNDING IN MEDICATION ADHERENCE MODELING  
Slejko JF1, Garrison L2, Willke RJ3 
1University of Washington, Seattle, WA, USA, 2University of Washington School of Pharmacy, 
Seattle, WA, USA, 3Pfizer Primary Care, New York, NY, USA  
OBJECTIVES: It is well-established that patients’ medication adherence is often 
suboptimal and variable in chronic disease settings, but less is known about the 
association between adherence and outcomes, in part due to potential 
confounding by unobserved disease severity when using claims data. Our 
objective was to estimate adherence unexplained by observed characteristics 
and use this estimate to proxy severity, which could motivate better adherence 
but also worsen outcomes. METHODS: A sample of the IMS LifeLink Health Plan 
Claims Database was used to identify a cohort of 26,893 primary prevention 
statin users. Adherence was estimated as the yearly proportion of days covered 
in beginning with the index statin prescription. A finite mixture model (FMM) 
was used to predict a posteriori the membership to better or worse adherer types. 
Using OLS regression adjusting for patient characteristics and the ‘healthy 
adherer effect’, the determinants of this probability were estimated. A residual 
inclusion estimation approach was used in a Cox proportional hazards model to 
estimate the effect of adherence on cardiovascular events. RESULTS: In a sample 
of new statin users, groups of low- and high-adherers existed. While year one 
adherence was not associated with cardiovascular events, year two mean 
adherence was (0.49 vs. 0.46, P<0.001). In the second year of statin use, the 
probability of being a high-adherer increased for males, those over 65 years and 
‘healthy adherers’. The Cox model adjusting for the covariates and residuals 
showed that as year two adherence increased, CV hazard decreased by 38% 
(P>0.001), versus a 20% reduction when the residual was not included. The 
included residuals per se increased hazard by 28% (P=0.04), consistent with a 
disease severity effect. CONCLUSIONS: FMM estimation reveals adherence 
‘types’. Estimating the probability of the ‘type’ allows isolation of a measure to 
address unobserved characteristics, such as disease severity, when modeling 
outcomes.  
 
PODIUM SESSION II:  
RESEARCH ON METHODS – MODELING STUDIES  
 
MO1  
MODELING FUTURE PREVALENCE OF NEUROLOGICAL CONDITIONS AND 
DEMAND FOR PHARMACEUTICALS IN THE UNITED STATES  
Gallo P, Dall T, Storm M, Chakrabarti R 
IHS, Washington, DC, USA  
OBJECTIVES: Accurately forecasting future disease prevalence and resulting 
demand for pharmaceuticals requires modeling changes in demographics, 
economic considerations, health care policy, disease risk factors, and treatment 
options. This study forecasts future neurological condition prevalence and 
related use of prescribed medications. METHODS: Using a microsimulation 
approach, we model future prevalence of neurological conditions and 
pharmaceutical use for each person in a stratified random sample (n~3M) of the 
population in the United States. The population database uses statistical 
matching to combine (1) population and economic data from the American 
Community Survey, (2) health data from the Behavioral Risk Factor Surveillance 
System, and (3) health data from National Nursing Home Survey. Sample 
weighting is derived from Census Bureau population projections. Logistic 
regression analysis with the Medical Expenditure Panel Survey estimates the 
propensity of people with neurological conditions to use prescribed medications 
to treat Alzheimer’s, attention deficit hyperactivity disorder, cerebral 
degeneration, epilepsy, extrapyramidal disease not elsewhere classified, mental 
retardation, migraine, mononeuritis of limb, multiple sclerosis, Parkinson’s, and 
sleep disorders. Forecasts through 2030 consider household income and 
demographic trends, and improved medical coverage under health care reform. 
RESULTS: In 2012, 26.6 million people (9% of US population) had a diagnosed 
neurological condition. Between 2012 and 2030, the population with neurological 
conditions will grow by 17% with the largest percentage growth occurring in 
Arizona (62% growth), Nevada (56%), and Florida (55%). Conditions with the 
largest percentage growth in prevalence are cerebral degeneration (72% growth), 
Parkinson’s disease (60%) and Alzheimer’s disease (59%). Use of medications will 
grow 2-3% through expanded medical coverage under PPACA. CONCLUSIONS: 
Prevalence rates for diagnosed and treated neurological conditions are projected 
to grow at similar rates over the next 20 years. Given the large increase in 
prevalence, the utilization of treatments (e.g., levodopa, MAOIs, cholinesterase 
inhibitors, and memantine) will rise accordingly.  
 
MO2  
REANALYZING CAROTID ARTERY STENOSIS TREATMENT CLINICAL TRIAL 
RESULTS FROM A BAYESIAN PERSPECTIVE  
Smolen HJ 
Medical Decision Modeling Inc., Indianapolis, IN, USA  
Frequentist statistics typically examines the null hypothesis that no difference 
exists between the competing strategies. Bayesian statistics permits the 
calculation of the probability that a treatment is superior based on observed data 
and prior information. Output of Bayesian analysis allows the observation of 
how prior information affects the output, especially as new information builds 
on the prior information. OBJECTIVES: To further analyze using Bayesian 
methods clinical trial results for the treatment of asymptomatic carotid artery 
stenosis (surgery vs. medical management) whose results were previously 
reported using frequentist methods. METHODS: The outcome of interest was the 
mean difference in the probability of stroke or perioperative death between 
carotid endarterectomy (CEA) and aggressive medical management (AMM). The 
prior distribution came from the results of the Asymptomatic Carotid 
Atherosclerosis Study (ACAS). The likelihood distribution was sourced from the 
Asymptomatic Carotid Surgery Trial (ACST). The Metropolis-Hastings Markov 
chain Monte Carlo sampling algorithm was used to approximate the posterior 
distribution. A 4% mean difference was chosen as the threshold for clinical-
economic significance. In sensitivity analysis, the prior distribution was replaced 
with results of The European Carotid Surgery Trialists Collaborative Group (ECST) 
study. RESULTS: The likelihood distribution (ASCT results) had an 86.5% 
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probability that the outcome of interest exceeded the threshold. The posterior 
distribution had a 93.0% probability. When data from the ECST study formed the 
prior distribution, the posterior distribution had only a 57.5% probability of 
exceeding the threshold. This reflects a revised prior which included a lower 
(relative to ACAS) expectation of stroke in the AMM population as informed by 
ECST data. CONCLUSIONS: Bayesian analysis allows the incorporation of 
differing prior information, whether representing clinical opinion or clinical 
trials. This permits the observation of how differing priors affect the posterior 




APPLIED CONTRIBUTIONS TO THE EQ-5D HEALTH UTILITY INDEX  
Ghushchyan VH1, Sullivan PW2, Libby AM3 
1University of Colorado Anschutz Medical Campus, School of Pharmacy, Aurora, CO, USA, 2Regis 
University School of Pharmacy, Denver, CO, USA, 3University of Colorado, Denver, Aurora, CO, USA  
OBJECTIVES: The objective was to identify the optimal statistical method for 
regression analysis of the EQ-5D index. Specifically, we compared the 
performance of alternative regression methods in estimating incremental 
preference-based health related quality of life scores from the EQ-5D index. 
Importance of this work is high as preference-based scores derived from the EQ-
5D index are used to calculate quality-adjusted life years (QALYs), the most 
common measure of health outcomes used in cost-effectiveness analysis. Many 
health utility variables are censored from the top by construction, i.e. full health 
at unity. This is a utility measurement dilemma as 46% of US respondents report 
a perfect EQ-5D score. Also, EQ-5D is treated as a continuous variable; however 
due to its derivation algorithm there is a gap nearly equivalent to one standard 
deviation in the US preference-based scores of the EQ-5D index (no values 
between 0.8603 and 1). METHODS: Simulation analyses were implemented to 
compare the performance of OLS, median regression, Tobit, and robust 
extensions of Tobit models. First, pooled 2000-2003 Medical Expenditure Panel 
Survey data was randomly divided into independent derivation and validation 
sets to estimate the relationship between the EQ-5D index and SF-12 physical 
summary scores. Second, the performance of the same estimation methods was 
compared in a Monte Carlo simulation under ten non-normal distributions. 
RESULTS: Median regression outperformed all other methods in the first 
simulation analysis followed by the re-censored Tobit method. Median 
regression also resulted in the smallest mean squared prediction errors in the 
Monte Carlo simulations, followed by the Tobit method with logistic distribution. 
CONCLUSIONS: Median regression appears to be the most robust method to use 
in regression analysis of the EQ-5D index. If normality and homoscedasticity 
assumptions are not met, then logistic-Tobit regression can be used as a robust 
extension of the classical Tobit method.  
 
MO4  
EXAMINING ONTARIO'S UNIVERSAL INFLUENZA IMMUNIZATION PROGRAM 
WITH A NEW DYNAMIC INFLUENZA MODEL  
Thommes EW1, Bauch CT2, Meier G3, Chit A4 
1GlaxoSmithKline Canada, Mississauga, ON, Canada, 2University of Guelph, Guelph, ON, 
Canada, 3GlaxoSmithKline Vaccines, King of Prussia, PA, USA, 4(formerly GlaxoSmithKline) 
Sanofi Pasteur Canada, Toronto, ON, Canada  
OBJECTIVES: In 2000, Ontario initiated the world’s first universal influenza 
immunization program (UIIP). Our objective was to simulate the effect of this 
program on influenza attack rates using a new multi-strain dynamic influenza 
model. We compared our model results to a previous study of pre- and post-UIIP 
rates of influenza-associated events in Ontario. METHODS: Our model is age-
stratified, compartmental, and explicitly tracks two A strains (H1N1, H3N2) and 
two B lineages (Victoria, Yamagata). It also incorporates transmission rate 
seasonality, and accounts for non-homogeneous mixing among age groups via a 
contact matrix. U.S. age-stratified average yearly attack rates and the fraction of 
influenza A versus B cases were used as calibration targets. The resulting 
posterior sets of natural history parameters were run together with Ontario 
demographic and vaccine coverage data. RESULTS: Our simulations showed the 
following post-UIIP reduction in yearly attack rate: <5yrs: 48(31-62)%; 5-19yrs: 
49(33-64)%; 20-49yrs: 52(36-66)%; 50-64yrs: 58(42-71)%; 65-74yrs: 59(43-72)%; 75-
84yrs: 58(41-71)%; 85+yrs: 57(40-70)%. We compared our results to Kwong et al. 
(2008, PLoS Med 5(10): e211)’s analysis of post-UIIP reductions in influenza-
associated events, making the assumption that within each age group, event 
rates scale linearly with attack rates. Though qualitatively similar, overall their % 
reductions are at the upper end of our results. CONCLUSIONS: Our model results 
support the conclusion that Ontario’s Universal Influenza Immunization 
Program has brought about a significant reduction in the province’s incidence of 
influenza. Though the relative increase in vaccine uptake due to the UIIP was 
greatest below age 50, reductions in attack rate were greatest in ages 50 and 
over, indicating indirect benefit for the elderly. Reductions inferred by Kwong et 
al. (2008) are on the high side of our results, but this is consistent with their 
assertion that post-UIIP influenza seasons across Canada were intrinsically less 
severe during the study period. 
 
PODIUM SESSION II:  
PATIENT PROTECTION AND AFFORABLE CARE ACT & OTHER HEALTH CARE 
REFORM STUDIES  
 
PP1  
THE IMPACT OF MASSACHUSETTS HEALTH CARE REFORM ON PATIENT 
OUTCOMES  
Sulham K, Armstrong S, Abraham J, Garfield S 
GfK Bridgehead, Wayland, MA, USA  
OBJECTIVES: Key provisions of the 2006 Massachusetts health care reform and 
national legislation passed in 2010 were individual mandates to obtain health 
insurance. Increasing health insurance coverage is thought to lead to increased 
access to primary/preventive health care and improved patient outcomes. We 
examined the impact of Massachusetts health reform on preventable 
hospitalizations and cancers. METHODS: The Healthcare Cost and Utilization 
Project (HCUP), National Program of Cancer Registries (NPCR), and Surveillance, 
Epidemiology and End Results (SEER) databases were analyzed. Based on AHRQ’s 
Prevention Quality Indicators, preventable hospitalizations related to diabetes, 
hypertension, asthma, chronic obstructive pulmonary disease, and congestive 
heart failure (CHF) were analyzed. In addition, we examined incidence of 
preventable cancers (cervical and colon). Data from 2005 were compared to 
2009/2010 data; changes were examined both in Massachusetts and compared to 
national trends. RESULTS: The proportion of uninsured patients in 
Massachusetts decreased in 2010 compared to 2005 across all 5 categories of 
preventable hospitalizations. In Massachusetts, preventable discharges 
decreased only for diabetes and CHF. While the magnitude of decrease was 
greater in diabetes (-0.02% Massachusetts vs. -0.004% nationally), this trend was 
reversed in CHF (-0.17% vs. -0.31%). Results were similarly mixed across the 
remaining preventable hospital conditions. SEER data indicate that incidence of 
cervical and colon cancer decreased in both Massachusetts (-3.2/100,000 and  
-5.4/100,000 for cervical and colon cancer, respectively) and nationally  
(-1.2/100,000 and -3.6/100,000) from 2005-2009: the magnitude of decrease was 
larger in Massachusetts. Similar trends in colon cancer were found in NPCR data: 
incidence of colon cancer declined by 10.4/100,000 patients in Massachusetts 
compared with 6.9/100,000 nationally. CONCLUSIONS: Massachusetts health 
care reform has increased insurance coverage, though its impact on patient 
outcomes is less clear. As similar national legislation is implemented, research is 
needed to determine whether and how increased insurance coverage can be 
linked to improved patient outcomes.  
 
PP2  
THE IMPACT OF PATIENT PROTECTION AND AFFORDABLE CARE ACT 
REGULATIONS ON DRUG MANUFACTURERS' MEDICAID MARKET SEGMENT 
PROFITABILITY  
Chen T, Cost P, Gaitonde P 
HERON Evidence Development LLC, Somerville, NJ, USA  
OBJECTIVES: This study assesses the financial impact of Patient Protection and 
Affordable Care Act (PPACA) regulations on the pharmaceutical industry. 
METHODS: U.S. Public Law was searched from 2007 - 2012 to identify profit-
impacting regulatory changes on pharmaceutical and biotechnology 
manufacturers. Relevant results were then juxtaposed against aggregated and 
standardized Medicaid General Ledger accounts. A simple predictive model was 
built to examine the relationship. RESULTS: Public Law 111-148, Sec. 2501 
PRESCRIPTION DRUG REBATES indicated a change, effective as of March 23, 2010, 
increasing the minimum Medicaid Drug Rebate from 15.1% to 23.1% of the 
Average Manufacturer Price (AMP). The AMP is calculated as an aggregated 
average of all commercial sales transactions to and through retail community 
pharmacies. By modelling the top 100 manufacturers' average profit measures, it 
is estimated that the industry, on average, stood to lose a minimum of 8% in 
profitability in the Medicaid market segment. The Medicaid market segment 
comprises approximately 20% of all U.S. manufacturer sales, suggesting the 
PPACA could have a considerable impact on pharmaceutical profits overall. 
CONCLUSIONS: Basic statistical methods suggest that PPACA regulations may 
directly impact pharmaceutical company profits. Given the significant 
consolidation, acquisition, divestiture, and reorganization activities during this 
time period, it is possible that these regulations are indirectly reshaping the 
pharmaceutical industry landscape. Regression analyses should be conducted to 
analyze the link between the Medicaid rebate increases with manufacturer 
organizational change and subsequent business outcomes.  
 
PP3  
TRANSFORMATION OF SERVICES AND CARE PATHWAY REDESIGN IN THE NHS: 
FURTHER REFORMS IN HEALTH POLICY  
Mallinson M, King P 
Access Partnership, London, UK  
OBJECTIVES: The NHS is meeting efficiency savings through 4 areas: quality, 
innovation, productivity & prevention (QIPP). There is currently a considerable 
degree of uncertainty from the Department of Health (DH) as to whether the 
demand for health care is being managed in ways that inappropriately restricts 
patients’ access to care. Reducing demand and redesigning care pathways to 
treat patients in the most appropriate setting are key ways of generating savings. 
However transforming services within a prospective payment driven systems is 
fraught with difficulty. A review was undertaken of current Health Policies and 
Independent Government office findings e.g. National Audit Office (NAO) as to 
the likely reality of achieving efficiency saving via this route. METHODS: A 
survey of PCT clusters and NAO findings was undertaken to understand how 
these policy initiatives were being introduced and to understand the barriers to 
services transformation. RESULTS: In 2011-12 47% of PCT clusters reinvested less 
than a quarter of their cash releasing savings in transforming services. The 
perceived barriers to services transformation were perceived as; Lack of 
measures to invest first e.g. in community services; organizational barriers 
between health & social care including information sharing and differing 
financial priorities; lack of influence over acute providers; organizational barriers 
between acute and community services; some transformations would be better 
enforced at a regional or national level; staff across patient care pathways do not 
have the right skills; lack of evidence to convince stakeholders of the benefits of 
